Scott Siera's practice focuses on patent prosecution in the biotechnology space. Scott assists small and large companies with patent prosecution, and counseling on related to issues of infringement, validity, and licensing. He represents clients in a variety of technology areas, including antibodies, microbiology, molecular diagnostics, synthetic biology, and agriculture.
Scott received his Ph.D. in molecular biology from U.C. Berkeley. His dissertation research related to regulation of gene expression and control of cell fate decisions during development.
Intellectual Property Considerations for the Microbiome: Personalized Strategies for a Diverse Space
PTAB holds Genentech's antibody purification method claims unpatentable as anticipated and obvious
Federal Circuit Finds That a Variant Polypeptide Sequence Infringes Under the Doctrine of Equivalents
Biotech Patent Applications May be Eligible to Receive Benefits From Ongoing USPTO Initiatives
FDA re-approves Mylotarg® antibody-drug conjugate seven years after it had been withdrawn from the market
Federal Circuit Finds That Fetal Diagnosis Claims Survive Written Description Attacks
In Helsinn Healthcare, the Federal Circuit Offers Guidance on the On-Sale Bar under the AIA
Preparing Biotech Patent Applications - Ten Strategies for Success
Not Just a Formality? USPTO Sequence Rules May Impact Existing Biotech Portfolios
Getting the Most from Biotech Patents in Europe Without Breaking the Bank: Selecting the Right Countries for Validation
Continental patents a la carte or prix fixe? Biotechnology considerations for the unitary patent in Europe